|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the current study, we have used a genomic probe from the MTC to study 51 Japanese patients having B-cell neoplasms with regard to rearrangement of LAZ3.
|
8063612 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BCL-6 rearrangements were detected both in the presence and in the absence of EBV infection of the tumor clone, but in no case were associated with activation of c-MYC or mutations of p53.
|
8025268 |
1994 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BCL6 rearrangements represent the first genetic lesion specifically and recurrently associated with DLLC and should prove useful for understanding the pathogenesis as well as for the clinical monitoring of these tumors.
|
8142643 |
1994 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Northern analysis of both rearranged and nonrearranged B-cell lymphoma cases showed similar levels of a transcript of approximately 3.8 kb, indicating that LAZ3 is broadly expressed in B-cell tumors and is not confined to rearranged cases.
|
7742550 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis of DLCL and FL biopsy samples showed that the BCL-6 protein is detectable in these tumors independent of the presence of BCL-6 gene rearrangements.
|
7795255 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytogenetic indicators of progression, including trisomy 7, trisomy 12, del(6)(q21q25), and structural alterations of 17p were less frequent in BCL6 rearranged DLLC compared to BCL6 germline tumors.
|
8750627 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To determine the functional consequences of these alterations, we have analyzed the structure of the rearranged BCL6 alleles and their corresponding RNA and protein species in two DLCL biopsies and one tumor cell line which carried the t(3;14)(q27;q32) translocation involving the BCL6 and immunoglobulin heavy-chain (IgH) loci.
|
8557040 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Southern blot analysis using probes from the major translocation cluster (MTC) region of the BCL6 revealed rearrangement in 21/197 patients (10.7%) with B-cell neoplasms studied at presentation, and 11/25 patients (44%) first studied at relapse.
|
8703825 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Strong nuclear positivity for the BCL-6 protein was detected in tumor (L&H) cells in all cases of NLPHD.
|
8555467 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At the N-terminus, C2H2-171 contains a POZ/tramtrack-like domain similar to that found in the tumor associated zinc finger proteins LAZ-3/BCL-6 and PLZ-F, as well as in non-zinc finger proteins.
|
9568537 |
1997 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms.
|
9209377 |
1997 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms.
|
9373196 |
1997 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study aimed at investigating the expression of the BCL-6 protein in acquired immune deficiency syndrome (AIDS)-related non-Hodgkin's lymphomas (AIDS-NHLs) and at comparing the expression pattern with the presence of Epstein-Barr virus (EBV) infection of the tumor clone.
|
9006332 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Strong nuclear positivity for bcl-6 was consistently detected in tumor (L&H) cells of nodular, lymphocyte-predominant Hodgkin's disease (NLPHD).
|
9209651 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, classic HD (CHD) is heterogeneous because the tumor cells of a fraction of CHD display the BCL-6(-)/syn-1(+) phenotype of post-GC B-cells, whereas another fraction of CHD is constituted by a mixture of tumor cells reflecting the GC (BCL-6(+)/syn-1(-)) or post-GC (BCL-6(-)/syn-1(+)) phenotypes.
|
9746758 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accordingly, an expanded survey in lymphoid malignancies showed that BCL-6 mutations are restricted to B cell tumors displaying GC or post-GC phenotype and carrying mutated Ig variable heavy chain sequences.
|
9751748 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Karyotypic analysis disclosed a t(3;22)(q27;q11), but the amount of tumor tissue was insufficient for molecular studies of the BCL-6 gene.
|
9856677 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequent BCL6 mutation in these tumors is consistent with our previous observation of hypermutation of the 5' noncoding region of the gene in lymphomas arising in the germinal-center B-cells.
|
9824205 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations were identified in the previously reported hypermutable region of BCL6 in all three tumors.
|
9796700 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In 6 samples, the nucleotide sequences showed evidence of intraclonal heterogeneity, consistent with a stepwise ongoing mutational process affecting the BCL-6 gene in the tumor cells.
|
10666217 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using these two long-distance PCR-based approaches, we cloned junctional areas of BCL6 translocations from a total of 58 cases of B-cell tumors.
|
10811103 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, no previous cytogenetic studies have found translocations involving the BCL6 locus (3q27) in HGBL, and the genetic basis underlying the BCL6 rearrangements in this tumor remains unclear.
|
10564588 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In these tumors BOB.1/OBF.1 is typically coexpressed with high levels of Bcl6.
|
10666379 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
On the basis of a comprehensive analysis of 308 B-cell neoplasms, we (1) expand the spectrum of tumors associated with BCL-6 mutations; (2) corroborate the notion that mutations cluster with GC and post-GC B-cell neoplasms; and (3) identify heterogeneous mutation frequency among B-lineage diffuse large cell lymphoma (B-DLCL) subsets.
|
10627476 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BCL-6 mRNA expression was assessed in tumor specimens obtained at the time of diagnosis from 22 patients with primary DLBCL.
|
11493437 |
2001 |